



Free Daily Pharma Industry Newsletter Every business day, *FiercePharma* updates pharmaceutical executives on the latest Pharma industry news and deals. Stay up to date on:

Pharma Company News | Generic Drug Companies | Pharmaceutical Marketing & Sales | FDA Regulations & Warnings | Phase IV Clinical Trials

[Click here](#) to see a sample.

We never sell or give away your contact information. Our readers' trust comes first.

EMAIL ADDRESS **SIGN ME UP**

Topics: Drug Safety

Gilead warns of fatal reaction to Sovaldi, Harvoni and heart drug

9 patients taking hep C drugs with amiodarone develop bradycardia, 1 dies and 3 need pacemakers

March 23, 2015 | By [Eric Palmer](#)

SHARE

Email

60

Tweet

146

Share

3

+1

Gilead Sciences' ([\\$GILD](#)) superselling hepatitis C drugs have hit a speed bump after 9 patients taking either [Harvoni](#) or [Sovaldi](#), as well as a common drug for heart arrhythmias, had serious reactions. One of the 9 had a heart attack and died. Three others had to receive pacemakers.



The FDA said on Friday it approved an update to the label warning of serious symptomatic bradycardia when the drugs are coadministered with amiodarone. In a letter to providers, Gilead said that 6 cases of symptomatic bradycardia happened within 24 hours of starting one of the drugs and the other three in two to 12 days. The drugmaker's share price was unfazed by the news.

Three of the 9 patients were receiving Gilead's combo drug Harvoni, a combination of Sovaldi (sofosbuvir) and ledipasvir. Five were getting Sovaldi along with Bristol-Myers Squibb's ([\\$BMY](#)) daclatasvir, a hepatitis C treatment which has been approved in Europe but which the FDA has responded to with a complete response letter asking for more data about how it interacts with other antiviral agents in treating hepatitis C. In the last case, the patient was taking Sovaldi along with Johnson & Johnson's ([\\$JNJ](#)) hep C treatment Olysio, a combination that the FDA approved in November. All were also getting amiodarone.

Webinar: The Basics of Biotech 101, 201 & 301

INDIVIDUAL SESSION: \$129, FULL SERIES: \$299

This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. This series provides an overview of the science and technology used to enable discovery and the processes scientists use to discover new therapeutics. [Register Now!](#)

Sign up for our FREE newsletter for more news like this sent to your inbox!

Gilead said in its letter that, "The mechanism of the potential interaction between amiodarone and Harvoni, or Sovaldi in combination with another DAA (direct antiviral agent) is unknown." It said it is recommended that patients who need amiodarone and Sovaldi and amiodarone be monitored in an inpatient setting for the first 48 hours, followed by daily outpatient or self-monitoring of their heart rate for at least the first two weeks of treatment. It said that because amiodarone has a "long half-life," patients who have just gone off of amiodarone ahead of starting Harvoni or Sovaldi along with a DAA should also be monitored.

Gilead's Sovaldi, the first all-oral interferon-free hepatitis C treatment to hit the market had unprecedented sales in its first year on the market, \$10.28 billion. The combo treatment Harvoni, which was approved by the FDA in October for hepatitis C virus genotype 1, has also been spectacular out of the gate, racking up \$2.13 billion in sales in the few months in 2014 that it was on the market. The drugmaker has taken huge criticism for how it set the retail prices for the 12-week treatments, \$85,000 for Sovaldi and \$94,500 for Harvoni. Gilead has defended the costs, saying that because both treatments have cure rates above 90%, payers will save in the long run by avoiding having to pay for hospital stays and high-cost liver transplants.

Prices of the drugs are starting to ease, however. When AbbVie ([\\$ABBV](#)) got its competing treatment, [Viekira Pak](#), approved by the FDA late last year, pharmacy benefits manager Express Scripts ([\\$ESRX](#)) cut an exclusive for that drug, setting off a price war that has led to deep discounts. Gilead has indicated that this year, its hep C gross-to-net adjustments--the difference between upfront pricing and sales after rebates--will run 46%. More than double the 22% applied last year.

Other drugs have received such warnings and it is always difficult to know how they might affect sales. The FDA in November added a description of a death to the label of Biogen's ([\\$BIIB](#)) hot multiple sclerosis pill [Tecfidera](#) after a patient developed a rare brain infection and died last year. The drug's sales in the fourth quarter will still up nearly three times to \$916 million compared with the fourth quarter of 2013.

- [here's the FDA release](#)
- [here's the Gilead letter](#)

Related Articles:

- [How big are Gilead's hep C drug discounts? Enough to spook investors](#)
- [Gilead's Sovaldi, Harvoni push its full-year sales to \\$25B; earnings beat expectations](#)
- [FDA slaps down Bristol-Myers' marketing pitch for hep C drug daclatasvir](#)
- [FDA adds PML death scenario to Tecfidera label](#)
- [Can J&J score sales with FDA's new Olysio-plus-Sovaldi approval?](#)

Sign up for our free newsletter **SIGN ME UP**

Filed Under [Gilead](#), [Harvoni](#), [Sovaldi](#)

COMMENTS

MOTIF INVESTING SPONSORED

Ex-Microsoft Exec Aims to Reinvent Investing

Motif Investing is a company that gives investors a low-cost way of creating their own portfolios or motifs - disrupting the traditional broker model. The company has JP Morgan (JPM) and Goldman Sachs (GS) as backers and cracked CNBC's 2014 Disruptor 50, coming in at number 4. Motif Investing allows users to create theme-based baskets of stocks.

[Learn More](#)



1 Comment [FiercePharma](#) Login

Recommend Share [Sort by Best](#)

Join the discussion...

Lynne Heal · 22 days ago
Many MS drugs are very dangerous

ALSO ON FIERCEPHARMA WHAT'S THIS?

Mallinckrodt ponies up \$2.3B for Ikaris and its neonatal respiratory ...

1 comment · a month ago

smb — Seriously, 2.3 billion for that piece of crap?! Go look at their old S1 - they couldn't even go public. Look at ...

Pfizer's Lyrica patent fight in England puts NHS docs, pharmacists on ...

1 comment · 15 days ago

fredd — The generic is terrible it doesn't work and isn't on a par with Lyrica. The people actually taking this med ...

AbbVie paid a 'lofty,' 'staggering,' 'astronomical' price for ...

2 comments · a month ago

Biotech BD — AbbVie may get an autoimmune drug, but it's not Imbruvica which showed fetal toxicity in ...

Top 15 pharma companies by 2014 revenue

10 comments · a month ago

Lynne Heal — NO MS drugs will ever cure MS ever too many make profits, shares and commissions on ...

Subscribe Add Disqus to your site Privacy **DISQUS**

JOIN 150,000+ INSIDERS SIGN UP FOR OUR NEWSLETTER

EMAIL ADDRESS **SIGN ME UP**

FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join thousands of pharma industry leaders who get *FiercePharma* via daily email. Sign up today!



POPULAR STORIES

MOST READ | **MOST SHARED**

- With U.S. sales suffering, GSK plots changes to quota-free pay model
- AstraZeneca's Onglyza 'mortality' risks noted by FDA reviewers
- Valeant CEO's 2014 pay pales in comparison to new EVP's \$50M-plus
- Sanofi won't discount Toujeo to Lantus
- The top 15 pharma companies by 2014 revenue

THE LIBRARY: WEBINAR

mHealth + Patient Engagement: A new connected health model

| THURSDAY, APRIL 16TH | 2PM ET / 11AM PT | PRESENTED BY: BBK WORLDWIDE

BBK Worldwide hosts a webinar exploring this new connected health model and its impact on clinical research. Join their expert panel, which includes **mHealth experts from BBK Worldwide, Oracle and Empatica**, and learn key strategies for successful implementation. Registration is free - [click here](#).

MORE ITEMS

What Do Customers Need in Oral Dose Development

DOWNLOAD TODAY!

LATEST COMMENTARY

- [Indivior CEO looks beyond 2015 after troubled Reckitt pharma unit's spinoff](#)
- [Get out your binoculars for FiercePharma's traditional holiday trend-spotting](#)
- [Pfizer believes a dose of confidence will help it sell biosimilars](#)
- [We publish, you pick: FiercePharma's 10 best-read stories of 2014](#)
- [Who are the stars of personalized meds? Roche, Novartis and J&J](#)

EVENTS

- Drug Development Immersion**
May 7-8 — Boston, MA — Sponsored by: BioTech Primer
- BIO International Convention**
June 15-18, 2015 — Pennsylvania Convention Center
- BioBasics: Biotech for the Non-Scientist**
December 3-4 — Boston, MA — Sponsored by: BioTech Primer

MORE EVENTS

Biopharma's Balancing Act: How Firms Are Managing Information Access and Security

DOWNLOAD TODAY!

PRESS RELEASES

- [MEDTRONIC ANNOUNCES CE MARK OF WORLD'S SMALLEST PACEMAKER, MICRA TRANSCATHETER PACING SYSTEM](#)
- [Boston Scientific Signs Strategic Alliance With Frankenman Medical](#)

FEATURED JOBS

> Need a job? Need to hire? Visit our jobs site.

Equipment Company

AstraZeneca and PatientsLikeMe announce global research collaboration

Medical Marijuana Liquid Extract May Bring Hope for Children with Severe Epilepsy

Ortho Kinematics Raises \$9.6 Million Series C Equity Financing

More Press Releases

A publication of FierceMarkets

FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get *FiercePharma* via daily email. [Click here](#) to get your free weekly email briefing today!

The FierceMarkets Network:

Telecom

- FierceCable
- FierceDeveloper
- FierceWireless:Europe
- FierceWirelessTech
- FierceOnlineVideo
- FierceTelecom
- FierceWireless

Marketing & Retail

- FierceCMO
- FierceMobileMarketer
- FierceRetail
- FierceRetailIT
- FierceMobileRetail

Healthcare

- FierceEMR
- FierceHealthcare
- FierceHealthFinance
- FierceHealthIT
- FierceHealthPayer
- FierceHealthPayerAntiFraud
- FierceMobileHealthcare
- FiercePracticeManagement
- Hospital Impact

Government

- FierceGovernment
- FierceGovernmentIT
- FierceHomelandSecurity
- FierceMobileGovernment
- FierceCities
- FierceGovHealthIT

Life Sciences

- FierceBiotechResearch
- FierceBiotech
- FierceBiotechIT
- FierceCRO
- FierceDiagnostics
- FierceDrugDelivery
- FierceMedicalDevices
- FiercePharma
- FiercePharmaAsia
- FiercePharmaManufacturing
- FiercePharmaMarketing
- FierceVaccines
- FierceAnimalHealth

Enterprise IT

- FierceBigData
- FierceCIO
- FierceContentManagement
- FierceDevOps
- FierceEnterpriseCommunicatio
- FierceITSecurity
- FierceMobileIT

Energy

- FierceEnergy
- SmartGridNews

Finance

- FierceCFO
- FierceFinanceIT

[Home](#) | [Subscribe](#) | [Manage Newsletter Subscriptions](#) | [Advertise](#) | [Contact](#) | [Mobile Apps](#) | [RSS](#) | [Privacy](#) | [Editors](#) | [List in Marketplace](#)
© 2015 FierceMarkets, a division of Questex Media Group LLC. All rights reserved.